Matches in Wikidata for { <http://www.wikidata.org/entity/Q94145027> ?p ?o ?g. }
Showing items 1 to 53 of
53
with 100 items per page.
- Q94145027 description "im Oktober 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q94145027 description "wetenschappelijk artikel" @default.
- Q94145027 description "наукова стаття, опублікована в жовтні 2019" @default.
- Q94145027 name "717. Lefamulin (LEF) vs. Moxifloxacin (MOX) in Patients With Community-Acquired Bacterial Pneumonia (CABP) at Risk for Poor Efficacy or Safety Outcomes: Pooled Subgroup Analyses From the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Pha" @default.
- Q94145027 name "717. Lefamulin (LEF) vs. Moxifloxacin (MOX) in Patients With Community-Acquired Bacterial Pneumonia (CABP) at Risk for Poor Efficacy or Safety Outcomes: Pooled Subgroup Analyses From the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Pha" @default.
- Q94145027 type Item @default.
- Q94145027 label "717. Lefamulin (LEF) vs. Moxifloxacin (MOX) in Patients With Community-Acquired Bacterial Pneumonia (CABP) at Risk for Poor Efficacy or Safety Outcomes: Pooled Subgroup Analyses From the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Pha" @default.
- Q94145027 label "717. Lefamulin (LEF) vs. Moxifloxacin (MOX) in Patients With Community-Acquired Bacterial Pneumonia (CABP) at Risk for Poor Efficacy or Safety Outcomes: Pooled Subgroup Analyses From the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Pha" @default.
- Q94145027 prefLabel "717. Lefamulin (LEF) vs. Moxifloxacin (MOX) in Patients With Community-Acquired Bacterial Pneumonia (CABP) at Risk for Poor Efficacy or Safety Outcomes: Pooled Subgroup Analyses From the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Pha" @default.
- Q94145027 prefLabel "717. Lefamulin (LEF) vs. Moxifloxacin (MOX) in Patients With Community-Acquired Bacterial Pneumonia (CABP) at Risk for Poor Efficacy or Safety Outcomes: Pooled Subgroup Analyses From the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Pha" @default.
- Q94145027 P1433 Q94145027-30E96B63-EF83-455A-AB9F-1DD37457E526 @default.
- Q94145027 P1476 Q94145027-7039C8EA-6285-482C-9AA1-103BF09AFB69 @default.
- Q94145027 P2093 Q94145027-23025733-EFDB-4E5F-8B0A-FC66D1EF2DD3 @default.
- Q94145027 P2093 Q94145027-7B771D08-B838-42DF-81B1-8F7AD7A78439 @default.
- Q94145027 P2093 Q94145027-7BC1A335-903C-450F-85C0-04FD3CF28A3A @default.
- Q94145027 P2093 Q94145027-B99AE7BA-39CD-4A67-B419-259038372B0E @default.
- Q94145027 P2093 Q94145027-B9E153AF-38D4-452A-A49A-49E2C5CC7748 @default.
- Q94145027 P2093 Q94145027-CB728701-4195-459F-A9BF-FB846B5BB055 @default.
- Q94145027 P2093 Q94145027-D4274A65-FE14-44DB-BF5E-B79E507EBB39 @default.
- Q94145027 P2093 Q94145027-F15F3214-A6B7-456D-9222-08D3A3A31220 @default.
- Q94145027 P275 Q94145027-63bcd6f4-efd0-4d7e-83f6-c8b2e5057154 @default.
- Q94145027 P304 Q94145027-BC829704-C524-44D8-9F60-A91ED7617CE7 @default.
- Q94145027 P31 Q94145027-4B112281-D537-4ADA-B1D2-7E8BD631F143 @default.
- Q94145027 P356 Q94145027-99410B37-AA6D-4B39-A143-2404C6FF6AC6 @default.
- Q94145027 P433 Q94145027-2EACBA0F-8722-4F70-A510-B9A8B3A53122 @default.
- Q94145027 P478 Q94145027-13168766-35E5-4A46-A976-9C2CB3B1EBA3 @default.
- Q94145027 P577 Q94145027-D5C38B73-6151-403D-AC47-8C12A101BC37 @default.
- Q94145027 P6216 Q94145027-c9f5fa2b-3b6c-4c1c-998a-9beacbfb0bc3 @default.
- Q94145027 P921 Q94145027-31A41B0C-278F-41C4-9724-3A06D9FED05F @default.
- Q94145027 P921 Q94145027-CA270DAC-FA1B-4136-9CF4-3FE751BAC759 @default.
- Q94145027 P932 Q94145027-27065644-BA9B-434F-9F24-B8FB5ED14A09 @default.
- Q94145027 P356 OFZ360.785 @default.
- Q94145027 P1433 Q27725953 @default.
- Q94145027 P1476 "717. Lefamulin (LEF) vs. Moxifloxacin (MOX) in Patients With Community-Acquired Bacterial Pneumonia (CABP) at Risk for Poor Efficacy or Safety Outcomes: Pooled Subgroup Analyses From the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Phase 3 Noninferiority Clinical Trials" @default.
- Q94145027 P2093 "Andrew F Shorr" @default.
- Q94145027 P2093 "Anita F Das" @default.
- Q94145027 P2093 "Christian Sandrock" @default.
- Q94145027 P2093 "Elizabeth Alexander" @default.
- Q94145027 P2093 "Gregory J Moran" @default.
- Q94145027 P2093 "Jennifer Schranz" @default.
- Q94145027 P2093 "Lisa Goldberg" @default.
- Q94145027 P2093 "Steven P Gelone" @default.
- Q94145027 P275 Q24082749 @default.
- Q94145027 P304 "S322-S323" @default.
- Q94145027 P31 Q13442814 @default.
- Q94145027 P356 "10.1093/OFID/OFZ360.785" @default.
- Q94145027 P433 "Suppl 2" @default.
- Q94145027 P478 "6" @default.
- Q94145027 P577 "2019-10-23T00:00:00Z" @default.
- Q94145027 P6216 Q50423863 @default.
- Q94145027 P921 Q3776920 @default.
- Q94145027 P921 Q424940 @default.
- Q94145027 P932 "6811254" @default.